GlassScriptPhysician profile
Charnes S Chiu
NPI 1548290869
$2,328.05
in general payments reported to CMS, 2019-2025
22 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $12.28 · 2021: $187 · 2022: $750 · 2023: $246 · 2024: $366 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $502.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $475.32 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $236.61 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $149.23 | 2022-2025 | Krystexxa, Tavneos |
| Ardelyx, INC. | $124.63 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $123.86 | 2019-2023 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $115.33 | 2019-2025 | Voyxact, Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.44 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $80.73 | 2022-2024 | Benlysta |
| Fresenius USA Marketing, INC. | $71.72 | 2023-2025 | Velphoro, Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $69.31 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $42.48 | 2019-2025 | |
| Outset Medical INC | $37.03 | 2022 | |
| Mallinckrodt Hospital Products INC. | $29.30 | 2025 | Acthar |
| Novo Nordisk INC | $28.40 | 2025 | Ozempic |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $25.00 | 2024 | |
| Daiichi Sankyo INC. | $24.98 | 2021 | |
| Apellis Pharmaceuticals, INC. | $24.72 | 2025 | |
| Cormedix INC. | $24.65 | 2024 | Defencath |
| Travere Therapeutics, INC. | $23.47 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.94 | 2019 | |
| Nxstage Medical, INC. | $15.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charnes Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.